Lan R
ORCID: 0000-0002-5612-880X
· 2 papers in corpus
2026
BackgroundIntroduced in 2002, the Essure® implant was promoted as a minimally invasive permanent contraceptive. After widespread use, increasing reports of adverse effects led to its global withdrawal in 2018. This study explores the experi…
article
2021
Abstract Aim The levonorgestrel‐releasing intrauterine (LNG‐IUS) system is an effective primary treatment for adenomyosis; however, it has high expulsion rates. We aimed to modify the system—allowing affixion to the myometrium—and evaluate …